FY2025 EPS Estimates for Opthea Cut by Leerink Partnrs

Opthea Limited (NASDAQ:OPT - Free Report) - Stock analysts at Leerink Partnrs cut their FY2025 earnings per share (EPS) estimates for Opthea in a report released on Monday, March 24th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($1.62) per share for the year, down from their prior forecast of ($1.15). Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Opthea's current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Opthea's FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at ($0.37) EPS.

OPT has been the subject of several other research reports. HC Wainwright lowered shares of Opthea from a "buy" rating to a "neutral" rating and dropped their price target for the stock from $12.00 to $2.00 in a research report on Tuesday, March 25th. Leerink Partners downgraded Opthea from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $12.00 to $1.00 in a report on Tuesday, March 25th. Oppenheimer cut Opthea from an "outperform" rating to a "market perform" rating in a report on Monday, March 24th. Jefferies Financial Group reissued an "underperform" rating and set a $1.00 price target (down previously from $8.00) on shares of Opthea in a research report on Tuesday, March 25th. Finally, Canaccord Genuity Group upgraded shares of Opthea to a "strong-buy" rating in a report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Opthea currently has an average rating of "Hold" and a consensus price target of $1.33.

Remove Ads

Opthea Stock Performance

Shares of Opthea stock remained flat at $3.41 during trading hours on Thursday. Opthea has a fifty-two week low of $1.79 and a fifty-two week high of $6.30. The company has a fifty day moving average price of $4.40 and a two-hundred day moving average price of $4.08.

Institutional Investors Weigh In On Opthea

A number of institutional investors have recently modified their holdings of OPT. ABC Arbitrage SA acquired a new position in Opthea in the fourth quarter worth $40,000. OLD Mission Capital LLC acquired a new position in shares of Opthea in the 4th quarter valued at about $42,000. Twin Lakes Capital Management LLC bought a new stake in shares of Opthea during the 3rd quarter valued at about $81,000. Citadel Advisors LLC bought a new stake in shares of Opthea during the 4th quarter valued at about $79,000. Finally, Jane Street Group LLC acquired a new stake in Opthea during the third quarter worth about $114,000. Institutional investors and hedge funds own 55.95% of the company's stock.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.